PT3377534T - Tratamento do cancro do pulmão utilizando uma combinação de um anticorpo anti-pd-1 e de um anticorpo anti-ctla-4 - Google Patents

Tratamento do cancro do pulmão utilizando uma combinação de um anticorpo anti-pd-1 e de um anticorpo anti-ctla-4

Info

Publication number
PT3377534T
PT3377534T PT168197184T PT16819718T PT3377534T PT 3377534 T PT3377534 T PT 3377534T PT 168197184 T PT168197184 T PT 168197184T PT 16819718 T PT16819718 T PT 16819718T PT 3377534 T PT3377534 T PT 3377534T
Authority
PT
Portugal
Prior art keywords
antibody
ctla
treatment
combination
lung cancer
Prior art date
Application number
PT168197184T
Other languages
English (en)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57680484&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3377534(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PT3377534T publication Critical patent/PT3377534T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PT168197184T 2015-11-18 2016-11-18 Tratamento do cancro do pulmão utilizando uma combinação de um anticorpo anti-pd-1 e de um anticorpo anti-ctla-4 PT3377534T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562257139P 2015-11-18 2015-11-18
US201662345314P 2016-06-03 2016-06-03

Publications (1)

Publication Number Publication Date
PT3377534T true PT3377534T (pt) 2025-07-10

Family

ID=57680484

Family Applications (1)

Application Number Title Priority Date Filing Date
PT168197184T PT3377534T (pt) 2015-11-18 2016-11-18 Tratamento do cancro do pulmão utilizando uma combinação de um anticorpo anti-pd-1 e de um anticorpo anti-ctla-4

Country Status (18)

Country Link
US (3) US11072657B2 (pt)
EP (2) EP4609915A3 (pt)
JP (3) JP2018538263A (pt)
KR (2) KR20180071386A (pt)
CN (1) CN108350081A (pt)
DK (1) DK3377534T3 (pt)
ES (1) ES3034582T3 (pt)
FI (1) FI3377534T3 (pt)
HR (1) HRP20250902T1 (pt)
HU (1) HUE072729T2 (pt)
LT (1) LT3377534T (pt)
PL (1) PL3377534T3 (pt)
PT (1) PT3377534T (pt)
RS (1) RS67037B1 (pt)
SI (1) SI3377534T1 (pt)
SM (1) SMT202500282T1 (pt)
TW (3) TWI821748B (pt)
WO (1) WO2017087870A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113967253A (zh) * 2012-05-15 2022-01-25 百时美施贵宝公司 通过破坏pd-1/pd-l1信号传输的免疫治疗
TN2017000440A1 (en) * 2015-04-17 2019-04-12 Bristol Myers Squibb Co Compositions comprising a combination of an anti-pd-1 antibody and another antibody
CN114591433A (zh) 2015-07-13 2022-06-07 西托姆克斯治疗公司 抗pd-1抗体、可活化抗pd-1抗体及其使用方法
HRP20250902T1 (hr) * 2015-11-18 2025-09-26 Bristol-Myers Squibb Company Liječenje raka pluća korištenjem kombinacije anti‑pd‑1 antitijela i anti‑ctla‑4 antitijela
EP4491237A3 (en) * 2016-10-28 2025-03-26 Bristol-Myers Squibb Company Methods of treating urothelial carcinoma using an anti-pd-1 antibody
US20200239577A1 (en) 2017-10-15 2020-07-30 Bristol-Myers Squibb Company Methods of treating tumor
CA3081696A1 (en) * 2017-11-07 2019-05-16 Memorial Sloan Kettering Cancer Center Inhibition of ctla-4 and/or pd-1 for regulation of t cells
EP3774911A1 (en) * 2018-03-30 2021-02-17 Bristol-Myers Squibb Company Methods of treating tumor
EP3938396A1 (en) * 2019-03-11 2022-01-19 Jounce Therapeutics, Inc. Anti-icos antibodies for the treatment of cancer
EP3937979A4 (en) * 2019-03-13 2023-03-08 Merck Sharp & Dohme LLC COMBINATIONAL ANTI-CANCER THERAPIES WITH CTLA-4 AND PD-1 BLOCKING AGENTS
KR20210146348A (ko) * 2019-03-28 2021-12-03 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
CN113891748A (zh) * 2019-03-28 2022-01-04 百时美施贵宝公司 治疗肿瘤的方法
AR122043A1 (es) * 2020-05-12 2022-08-03 Bristol Myers Squibb Co Dosificación y administración del anticuerpo anti-ctla-4 activable
US20230295301A1 (en) * 2020-07-21 2023-09-21 Shanghai Junshi Biosciences Co., Ltd. Anti-ctla-4 antibody and use thereof
WO2022087402A1 (en) 2020-10-23 2022-04-28 Bristol-Myers Squibb Company Lag-3 antagonist therapy for lung cancer
KR20230107309A (ko) 2020-11-10 2023-07-14 카탈임 게엠베하 항-gdf15 항체 및 암 치료용 투여 용법
EP4294531A4 (en) * 2021-02-18 2025-07-16 Qilu Puget Sound Biotherapeutics Corp COMBINATIONS OF ANTI-PD1 AND ANTI-CTLA4 ANTIBODIES
WO2024002074A1 (zh) * 2022-06-28 2024-01-04 齐鲁制药有限公司 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
EP1210428B1 (en) 1999-08-23 2015-03-18 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
IL148079A0 (en) 1999-08-24 2002-09-12 Medarex Inc Human ctla-4 antibodies and compositions containing the same
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
EP1261376A1 (en) 2000-01-27 2002-12-04 Genetics Institute, LLC Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof
ES2350687T3 (es) 2002-07-03 2011-01-26 Ono Pharmaceutical Co., Ltd. Composiciones de inmunopotenciación.
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
CA2647282A1 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
HRP20131167T1 (hr) 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
WO2009100140A1 (en) * 2008-02-04 2009-08-13 Medarex, Inc. Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
CN102203132A (zh) 2008-08-25 2011-09-28 安普利穆尼股份有限公司 Pd-1拮抗剂的组合物和使用方法
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
CA2777226A1 (en) * 2009-10-12 2011-04-21 Pfizer Inc. Cancer treatment
NZ628923A (en) 2009-11-24 2016-02-26 Medimmune Ltd Targeted binding agents against b7-h1
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
CA2828940C (en) 2011-03-10 2024-04-16 Provectus Pharmaceuticals, Inc. Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer
KR101970025B1 (ko) 2011-04-20 2019-04-17 메디뮨 엘엘씨 Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들
HRP20201595T1 (hr) 2011-11-28 2020-12-11 Merck Patent Gmbh Anti-pd-l1 protutijela i njihova uporaba
CN113967253A (zh) * 2012-05-15 2022-01-25 百时美施贵宝公司 通过破坏pd-1/pd-l1信号传输的免疫治疗
CA2877414A1 (en) * 2012-07-30 2014-02-06 Alex Wah Hin Yeung Live and in-vivo tumor specified cancer vaccine system
US20150231241A1 (en) * 2012-08-14 2015-08-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
US9789182B2 (en) * 2012-10-23 2017-10-17 Bristol-Myers Squibb Company Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer
EA034666B1 (ru) 2013-09-13 2020-03-04 Бейджин Свитзерланд Гмбх Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
EP3068425B1 (en) * 2013-11-11 2021-01-27 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
EA201691376A1 (ru) 2014-02-04 2017-01-30 Пфайзер Инк. Комбинация антагониста pd-1 и ингибитора vegfr для лечения рака
JP2017515859A (ja) 2014-05-15 2017-06-15 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｐｄ−１抗体と他の抗癌剤の組み合わせを使用する肺癌の処置
CA2955676A1 (en) * 2014-08-25 2016-03-03 Pfizer Inc. Combination of a pd-1 antagonist and an alk inhibitor for treating cancer
US20160362489A1 (en) * 2015-04-28 2016-12-15 Bristol-Myers Squibb Company Treatment of PD-L1-Positive Melanoma Using an Anti-PD-1 Antibody
CN107735097A (zh) * 2015-04-30 2018-02-23 希斯托金公司 用于治疗癌症或免疫性疾病的细胞外基质组合物
WO2016191751A1 (en) 2015-05-28 2016-12-01 Bristol-Myers Squibb Company Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
JP2018522887A (ja) * 2015-07-14 2018-08-16 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 免疫チェックポイント阻害剤を使用する癌の処置法
HRP20250902T1 (hr) * 2015-11-18 2025-09-26 Bristol-Myers Squibb Company Liječenje raka pluća korištenjem kombinacije anti‑pd‑1 antitijela i anti‑ctla‑4 antitijela
WO2017132508A1 (en) 2016-01-27 2017-08-03 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
MA44483A (fr) * 2016-03-24 2019-01-30 Millennium Pharm Inc Procédés pour traiter des événements indésirables gastro-intestinaux d'origine immunitaire dans des traitements oncologiques immunitaires
WO2017176925A1 (en) 2016-04-05 2017-10-12 Bristol-Myers Squibb Company Cytokine profiling analysis for predicting prognosis of a patient in need of an anti-cancer treatment
WO2017210631A1 (en) 2016-06-03 2017-12-07 Bristol-Myers Squibb Company Anti-pd-1 antibody for use in a method of treatment of recurrent small cell lung cancer
WO2017210624A1 (en) 2016-06-03 2017-12-07 Bristol-Myers Squibb Company Anti-pd-1 antibody for use in a method of treating a tumor
EP3774911A1 (en) * 2018-03-30 2021-02-17 Bristol-Myers Squibb Company Methods of treating tumor
JP2022505647A (ja) * 2018-10-23 2022-01-14 ブリストル－マイヤーズ スクイブ カンパニー 腫瘍の処置方法

Also Published As

Publication number Publication date
US20180371092A1 (en) 2018-12-27
RS67037B1 (sr) 2025-08-29
US11072657B2 (en) 2021-07-27
HRP20250902T1 (hr) 2025-09-26
TW202227132A (zh) 2022-07-16
PL3377534T3 (pl) 2025-09-01
EP3377534A1 (en) 2018-09-26
SMT202500282T1 (it) 2025-09-12
EP4609915A3 (en) 2025-11-19
FI3377534T3 (fi) 2025-08-22
TW201731527A (zh) 2017-09-16
TWI821748B (zh) 2023-11-11
KR20180071386A (ko) 2018-06-27
WO2017087870A1 (en) 2017-05-26
KR20260020215A (ko) 2026-02-10
JP2018538263A (ja) 2018-12-27
US20250154257A1 (en) 2025-05-15
US12528865B2 (en) 2026-01-20
ES3034582T3 (en) 2025-08-20
DK3377534T3 (da) 2025-08-18
EP4609915A2 (en) 2025-09-03
TWI912619B (zh) 2026-01-21
TW202408573A (zh) 2024-03-01
JP2025029025A (ja) 2025-03-05
SI3377534T1 (sl) 2025-09-30
LT3377534T (lt) 2025-08-11
US20220017619A1 (en) 2022-01-20
CN108350081A (zh) 2018-07-31
JP2022068352A (ja) 2022-05-09
TWI795347B (zh) 2023-03-11
EP3377534B1 (en) 2025-06-18
HUE072729T2 (hu) 2025-12-28

Similar Documents

Publication Publication Date Title
HUE072729T2 (hu) Tüdõrák kezelése anti-PD-1 antitest és anti-CTLA-4 antitest kombinációjának felhasználásával
IL282962A (en) Anti-PD-1 antibodies and methods of using them
IL268479A (en) Anti-PD-1 antibodies for the treatment of lung cancer
IL267804A (en) Methods for treating cancer with anti-pd-1 antibodies
IL262892A (en) Anti pd-1 and anti-lag3 antibodies for cancer treatment
IL259924A (en) Combination of anti-pd-1 antibodies and bispecific anti-cd20/anti-cd3 antibodies to treat cancer
IL253462B2 (en) Cancer treatment with monoclonal antibodies against a latency-related peptide
IL255569A (en) Methods of treating cancer using anti-ox40 antibodies
IL252280A0 (en) Anti pd-1 antibodies and methods of using them
SG10201913500TA (en) Anti-ctla-4 antibodies and methods of use thereof
IL248528A0 (en) Anti-b7-h1 and anti-ctla-4 antibodies for the treatment of non-small cell lung cancer
IL259713B2 (en) Anti-DR5 antibodies and methods of using them
SMT202500445T1 (it) Anticorpi anti-pd-1 per l'uso nel trattamento del cancro
IL307850A (en) A combination of a histone deacetylase inhibitor and an antibody against programmed cell death protein 1 for the treatment of cancer
IL266990A (en) Methods for treating cancer using anti-pd-l1 antibodies and antiandrogens
IL272669A (en) Combination therapy with a combination of anti-CSF1R and anti-PD-1 antibodies for pancreatic cancer
IL268460A (en) Treatment of bladder cancer with an antibody against pd-l1
HK40018984A (en) Anti-pd-1 antibodies for treatment of lung cancer